Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease
Critical Care volume 24, Article number: 318 (2020)
The pulmonary renin angiotensin (Ang) system (RAS) comprises two pathways whose balance is important for lung homeostasis. Endothelial ACE generates Ang II, acting on AT1 receptors to promote vasoconstriction and pro-inflammatory effects, whereas epithelial ACE2 cleaves Ang II into Ang1–7, acting on the Mas receptor to exert vasodilatory and anti-inflammatory effects. A shift towards predominant ACE-dependent Ang II formation has been postulated as an important pathophysiological mechanism in various forms of ARDS .
SARS-CoV-2 uses lung ACE2 as its cellular receptor, resulting in ACE2 degradation and ACE/ACE2 imbalance, which could drive Ang II-mediated vascular inflammation and lung injury in severe COVID-19 disease . Furthermore, Ang II induces the release of aldosterone, which can promote further vascular damage via mineralocorticoid receptor (MR) activation . Aldosterone also exerts multiple actions on immune cells, which express the MR . MR activation polarizes macrophages towards the M1 pro-inflammatory phenotype. In lymphocytes, MR activation promotes the differentiation of pro-inflammatory Th17 CD4+ cells and of cytotoxic IFNγ+-CD8+ T cells (Fig. 1), indicating that MR activation in immune cells promotes a hyperinflammatory profile . It is particularly noticeable that Th17 T cells increase and high CD8+ cells cytotoxicity have been proposed to be involved in the hyperinflammatory state characterizing COVID-19 ARDS .
Dysregulated RAS signaling with enhanced aldosterone-mediated MR activation could represent an important link between SARS-CoV-2/ACE2 interaction and inflammatory lung injury, suggesting an interesting therapeutic potential of RAS inhibitors  and in particular MR antagonists. However, it has been claimed that RAS inhibitors could enhance ACE2 expression, which might represent a possible drawback of this therapeutic strategy, as this might influence SARS-CoV-2 infectivity . Importantly, in contrast to other RAS inhibitors, the MR antagonist spironolactone also possesses significant anti-androgenic actions . Such effects may be particularly useful in the context of SARS-CoV-2 infection, by inhibiting the androgen-dependent expression of TMPRSS2, a transmembrane protease crucial for viral entry through its priming effect on the viral S protein . Therefore, by its dual actions as an MR antagonist and an androgenic inhibitor, spironolactone might provide significant benefits in COVID-19 ARDS. Naturally, the primary action of spironolactone (reduction of pulmonary edema) would also be beneficial in COVID-19 ARDS. Thus, we hypothesize that through its combined pharmacological actions, spironolactone may provide therapeutic benefit, when applied in the later stage of COVID-19 ARDS. Clinical trials may be warranted to evaluate its therapeutic potential.
Availability of data and materials
South AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16:305–7.
Biwer LA, Wallingford MC, Jaffe IZ. Vascular mineralocorticoid receptor: evolutionary mediator of wound healing turned harmful by our modern lifestyle. Am J Hypertens. 2019;32:123–34.
Belden Z, Deiuliis JA, Dobre M, Rajagopalan S. The role of the mineralocorticoid receptor in inflammation: focus on kidney and vasculature. Am J Nephrol. 2017;46:298–314.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2.
Wang X, Dhindsa R, Povysil G, Zoghbi A, Motelow J, Hostyk J, Nickols N, Rettig M, Goldstein DB. TMPRSS2 Transcriptional Inhibition as a Therapeutic Strategy for COVID-19. 2020. p. 2020030360. https://doi.org/10.20944/preprints202003.0360.v2.
Ethics approval and consent to participate
Consent for publication
No competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Liaudet, L., Szabo, C. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease. Crit Care 24, 318 (2020). https://doi.org/10.1186/s13054-020-03055-6